SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Attention centers on Corvuss soquelitinib atopic dermatitis data, which bullish traders view as encouraging evidence for the drugs broader potential. The stocks sharp negative reaction to the presentation has prompted debate over whether investor expectations were overbuilt, with skeptics citing unanswered safety questions and longs blaming short selling.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines positive Phase 3 results for daraxonrasib and its FDA approval for metastatic pancreatic cancer remain the main focus, with traders weighing the drugs commercial potential against concerns about weaker results in some KRAS subgroups and emerging competitors. Discussion also centers on the upcoming earnings report and whether early launch performance can support the companys valuation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Strong quarterly results and managements outlook are drawing attention, with traders focused on advanced negotiations to supply natural gas to data centers and other large power users. The reaction is broadly bullish on growth prospects and rising distributions, though some investors are frustrated that the unit price has shown a muted response.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

In recognition of National Lung Cancer Awareness Month, bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for early lung cancer detection with its noninvasive CyPath Lung test, will join physicians, patients and other healthcare providers at the Lung...

bioAffinity Technologies to Present New Perspectives on CyPath Lungs Use for Cancer Risk Assessment at CHEST 2026

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest...

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians...

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing...

bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its previously announced registered direct offering of shares of common stock (or...

WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct...

bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into a definitive agreement with an institutional investor to sell shares of common...

These Stocks are Lighting it Up

These names stand out for very different reasons: NeOnc Technologies (NASDAQ:NTHI), Hyperfine (NASDAQ:HYPR), bioAffinity Technologies (NASDAQ:BIAF), Profound Medical (NASDAQ:PROF), Wolfspeed (NYSE: WOLF) and Sunshine Biopharma (NASDAQ:SBFM).

bioAffinity’s Lung-Cancer AI Gets Japanese Patent Boost as CyPath Lung Sales Surge

bioAffinity Technologies (NASDAQ:BIAF) is adding another layer of protection around its most important commercial asset just as adoption of its CyPath Lung diagnostic is accelerating.

bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath Lung and AI-Built Algorithm

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Notice of Allowance indicating its intention to...

• Reported GAAP EPS of -$0.64 up 87.45% YoY
• Reported revenue of $1.51M up 18.99% YoY

bioAffinity Technologies continues to report significant net losses and rising operating expenses, while the company's cash and cash equivalents balance has decreased by $4.0 million since the end of 2025.

bioAffinity Technologies achieved strong commercial momentum with a 216% increase in CyPath Lung test volume and expanded its pipeline into asthma, COPD, and skin cancer therapeutics during the quarter.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BIAF Stock Gains As CyPath Sales Surge 146% In Q1

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>CyPath uses flow cytometry and AI to provide “likely” or “unlikely” malignancy results.</li><li>Rising pulmonary nodules and lung cancer survivors could drive market revenue to over $560 million.</li><li>bioAffinity’s commercial initiatives include expanding physician sites, peer education, and integration into clinical workflows.</li></ul>bioAffinity Technologies, Inc. (BIAF) announced on Wednesday that its CyPath Lung test has surpassed sales expectations in the first quarter of 2026, recording a 146% year-over-year increase in unit sales.CyPath Lung combines flow cytometry with AI to deliver clear “likely” or “unlikely” malignancy results to physicians. Real-world applications suggest the test can detect lung cancer at Stage 1A, improving treatment outcomes, and reduce unnecessary invasive procedures when malignancy risk is low.<h2 class="st-heading-2">Strong Market Demand</h2>Estimates from the U.S. Preventive Services Task Force suggest that indeterminate pulmonary nodules detected in the U.S. will increase 62%, from 2.9 million in 2025 to 4.7 million by 2030. The number of lung cancer survivors is also expected to rise from 680,000 to more than 871,000 over the same period.&nbsp;Capturing just 10% of these markets could generate $358 million in revenue for CyPath Lung, growing to over $560 million in five years, driven by a 10% compound annual growth rate fueled by broader screening adoption and AI-enhanced imaging technologies.<blockquote>“CyPath Lung is designed to address a critical gap in the diagnostic pathway by supporting lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance.”-Maria Zannes, President and CEO of bioAffinity Technologies</blockquote>Following the update, bioAffinity stock traded over 8% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘low’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Commercial Strategy Boosts Adoption</h2>bioAffinity has focused on CyPath Lung as its flagship product, expanding ordering sites, promoting peer-to-peer education among pulmonologists, and integrating the test into routine lung cancer risk assessment workflows.&nbsp;Revenue for CyPath Lung rose 87% year-over-year in 2025, while test units sold grew 99% compared to 2024.BIAF stock has gained over 260% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/msft-stock-struggles-weakest-magnificent-seven-in-q1-and-now-it-is-spending-5-5-b-more-on-ai/cZ7HZG9RInw">MSFT Stock Struggles As Weakest Of Magnificent Seven In Q1 – And Now It Is Spending $5.5B More On AI</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAffinity Technologies logo is displayed on the screen of a tablet.

bioAffinity Technologies, Inc. (BIAF) announced on Wednesday that its CyPath Lung test has surpassed sales expectations in the first quarter of 2026, recording a 146% year-over-year increase in unit sales.

The test is capable of identifying lung cancer at Stage 1A, enhancing chances for effective treatment.


Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.91
Prev Close	$3.03
Open	$3.04
Dividend Yield	0.00%
50-Day Moving Average	$6.15
Beta	1.67
Avg. Volume	8.86M
PE Ratio	-0.03

52-Week High	$80.70
52-Week Low	$2.66
Market Capitalization	$3.73M
EPS (Annual)	-$129.95
Price to Book	0.35
Revenue Per Employee	$108,104.54

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIAF Fundamentals